Durable swellable hydrogel matrix and methods

• US 20090081275A1
• Filed: 09/25/2008
• Published: 03/26/2009
• Est. Priority Date: 09/25/2007
• Status: Abandoned Application

• Current Assignee: Icnc Surmodics
• Original Assignee: Icnc Surmodics
• Inventors: Rolfes, Emily R., Chudzik, Stephen J., Reed, Pamela J.
• Application Number:
  US12/284,838
• Publication Number:
  US 20090081275A1
• Time in Patent Office: Days
• US Class Current: 424/423
• CPC Class Codes: C08G 65/3322 acyclic
• CPC Class Codes: C08J 3/075 Macromolecular gels
• CPC Class Codes: C08L 71/02 Polyalkylene oxides

Abstract

The invention provides biocompatible polymeric hydrogel matrices having excellent durability and swellability. The matrices are formed from a combination of linear and branched hydrophilic macromer compounds. The matrices can be used in association with a medical device or alone. In some methods the polymeric matrix is placed or formed at a target site in which the matrix swells and occludes the target area.

Claims

1. A biocompatible swellable or swollen polymeric matrix comprising first and second polymer-containing segments crosslinked via polymerized groups, wherein the first polymer-containing segment has a linear structure comprising a hydrophilic polymer portion and the second polymer-containing segment has a branched structure comprising hydrophilic polymer portions.

2. The biocompatible swellable or swollen polymeric matrix of claim 1 wherein the second polymer-containing segment having a branched structure comprises oxyalkylene polymer portions.

3. The biocompatible swellable or swollen polymeric matrix of claim 1 wherein the second polymer-containing segment has a molecular weight in the range of 300 Da to 20 kDa.

4. The biocompatible swellable or swollen polymeric matrix of claim 1 wherein the alkylene oxide polymer portions of the second polymer-containing segment independently have a molecular weight in the range of 500 Da to 2500 Da.

5. The biocompatible swellable or swollen polymeric matrix of claim 1 wherein the second polymer-containing segment has a branched structure with three alkylene oxide polymer portions.

6. The biocompatible swellable or swollen polymeric matrix of claim 1 wherein second polymer-containing segment having a branched structure comprises poly(ethylene glycol) portions.

7. The biocompatible swellable or swollen polymeric matrix of claim 1 wherein the second polymer-containing segment has a structure selected from the group consisting of:

8. The biocompatible swellable or swollen polymeric matrix of claim 1 wherein the first polymer-containing segment having a linear structure comprises a polymer selected from the group consisting of poly(vinylpyrrolidone) (PVP), poly(ethylene oxide) (PEO), poly(ethyloxazoline), poly(propylene oxide) (PPO), poly(meth)acrylamide (PAA) and poly(meth)acylic acid, poly(ethylene glycol) (PEG), copolymers of polyethylene glycol and polypropylene oxide (PEG-PPO), hydrophilic segmented urethanes, and polyvinyl alcohol.

9. The biocompatible swellable or swollen polymeric matrix of claim 1 wherein the first polymer-containing segment having a linear structure comprises an oxyalkylene polymer.

10. The biocompatible swellable or swollen polymeric matrix of claim 1 wherein the first polymer-containing segment having a linear structure comprise a hydrophilic polymer portion having a molecular weight of in the range of 100 Da to 5000 Da.

11. The biocompatible swellable or swollen polymeric matrix of claim 1 wherein the first polymer-containing segment and the second polymer-containing segment are present in the matrix at a weight ratio in the range of 100:

1 to 1;

100, respectively.

12. The biocompatible swellable or swollen polymeric matrix of claim 11 wherein the first polymer-containing segment and the second polymer-containing segment are present in the matrix at a weight ratio in the range of 50:

1 to 1;

10, respectively.

13. The biocompatible swellable polymeric matrix of claim 1 which is capable of swelling in water to a weight in the range of 1.5 to 10 times a weight of the matrix in a dehydrated form.

14. The biocompatible swellable polymeric matrix of claim 1 which exerts a swelling force in the range of 100 g/cm² to 2000 g/cm² upon hydration from a dehydrated form.

15. The biocompatible swellable polymeric matrix of claim 1 which is capable of swelling in water to a size in the range of about 150% to about 300% its size in a dehydrated form.

16. The biocompatible swellable or swollen polymeric matrix of claim 1 which is associated with an implantable medical device.

17. The biocompatible swellable or swollen polymeric matrix of claim 1 which is in the form of an overcoat on the implantable medical device.

18. The biocompatible swellable or swollen polymeric matrix of claim 1 comprising a radioopaque agent.

19. The biocompatible swellable or swollen polymeric matrix of claim 1 further comprising a third segment comprising a hydrophilic polymer comprising pendent reacted photogroups.

24. A method for treating a subject comprising a step of placing a biocompatible swellable or swollen polymeric matrix according to claim 1 at a target location in a subject.

25. The method of claim 24 resulting in a swollen polymeric matrix which occludes the target location.

20. A method for forming a biocompatible swellable or swollen polymeric matrix comprising steps of:

(a) providing a composition comprising

(i) a first compound having a linear structure comprising a hydrophilic polymer portion and a pendent polymerizable group, and

(ii) a second compound having a branched structure comprising oxyalkylene polymer portions and pendent polymerizable groups, and

(b) activating the polymerizable groups to cause crosslinking of the first and second compounds and matrix formation.

21. The method of claim 20 wherein the composition comprises the second compound in an amount of 5% wt solids or greater.

22. The method of claim 20 wherein the composition comprises the first compound in an amount in the range of 2% wt solids to 40% wt solids.

23. The method of claim 20 where, in step (a) the composition is provided to a target location on a subject, and in step (b) the polymerizable groups are activated to cause crosslinking of the first and second compounds and in situ matrix formation.